ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION
The invention relates to the use of compounds of general Formula (IA) wherein: A is an optionally substituted cycloalkane ring having 3 to 6 carbon atoms and attached at a single ring carbon atom thereof; Ar is phenyl or heteroaryl having 5 or 6 ring members, R1 and R2 independently are hydrogen, lo...
Saved in:
Main Authors | , , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
05.02.1998
|
Edition | 6 |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The invention relates to the use of compounds of general Formula (IA) wherein: A is an optionally substituted cycloalkane ring having 3 to 6 carbon atoms and attached at a single ring carbon atom thereof; Ar is phenyl or heteroaryl having 5 or 6 ring members, R1 and R2 independently are hydrogen, lower alkyl, lower alkoxy, halo, hydroxy, trifluoromethyl, nitro or amino, or R1 and R2 together form lower alkylenedioxy or optionally substituted benzo; and R3 is (i) -(CH2)nNR10, R11, in which n is 2 or 3 and R10 and R11 each are lower alkyl or R10 and R11 together with the nitrogen atom form a saturated azacyclic or azabicyclic ring system; or (ii) -(CH2)m-Q, in which m is 0 or 1 and Q is the residue of a saturated azacyclic or azabicyclic ring system coupled via a carbon atom thereof, or a pharmacologically acceptable salt thereof, for treatment of urinary incontinence or irritable bowel syndrome. The invention also relates to novel compounds encompassed by Formula (IA), pharmaceutical compositions thereof and preparation of the compounds.
La présente invention concerne l'emploi de composés de la Formule générale(IA) dans laquelle A représente un noyau cycloalcane éventuellement substitué possédant 3 à 6 atomes de carbone et lié à un atome de carbone à noyau unique correspondant; Ar représente phényle ou hétéroaryle possédant des éléments à 5 à 6 noyaux; R1 et R2 représentent, indépendamment l'un de l'autre, l'hydrogène, un alkyle faible, alcoxy faible, halo, hydroxy, trifluorométhyle, nitro ou amino, ou R1 et R2 forment ensemble un radical alkylénedioxy faible ou benzo éventuellement substitué, et R3 représente (i) -(CH2)nNR10, R11, dans lequel n vaut 2 ou 3, et R10 et R11 représentent chacun un alkyle faible ou R10 et R11 forment ensemble, avec l'atome d'azote, un système de noyaux saturé azacyclique ou azabicyclique ; ou (ii) -(CH2)m-Q, dans lequel m vaut 0 ou 1 et Q est le résidu d'un système de noyaux saturé azacyclique ou azabicyclique, système couplé via un atome de carbone de celui-ci, ou un sel pharmacologiquement acceptable de celui-ci, pour le traitement de l'incontinence urinaire ou le syndrome d'irritation intestinale. La présente invention concerne aussi des composés nouveaux inclus dans la Formule (IA), des compositions pharmaceutiques de ceux-ci et la préparation desdits composés. |
---|---|
AbstractList | The invention relates to the use of compounds of general Formula (IA) wherein: A is an optionally substituted cycloalkane ring having 3 to 6 carbon atoms and attached at a single ring carbon atom thereof; Ar is phenyl or heteroaryl having 5 or 6 ring members, R1 and R2 independently are hydrogen, lower alkyl, lower alkoxy, halo, hydroxy, trifluoromethyl, nitro or amino, or R1 and R2 together form lower alkylenedioxy or optionally substituted benzo; and R3 is (i) -(CH2)nNR10, R11, in which n is 2 or 3 and R10 and R11 each are lower alkyl or R10 and R11 together with the nitrogen atom form a saturated azacyclic or azabicyclic ring system; or (ii) -(CH2)m-Q, in which m is 0 or 1 and Q is the residue of a saturated azacyclic or azabicyclic ring system coupled via a carbon atom thereof, or a pharmacologically acceptable salt thereof, for treatment of urinary incontinence or irritable bowel syndrome. The invention also relates to novel compounds encompassed by Formula (IA), pharmaceutical compositions thereof and preparation of the compounds.
La présente invention concerne l'emploi de composés de la Formule générale(IA) dans laquelle A représente un noyau cycloalcane éventuellement substitué possédant 3 à 6 atomes de carbone et lié à un atome de carbone à noyau unique correspondant; Ar représente phényle ou hétéroaryle possédant des éléments à 5 à 6 noyaux; R1 et R2 représentent, indépendamment l'un de l'autre, l'hydrogène, un alkyle faible, alcoxy faible, halo, hydroxy, trifluorométhyle, nitro ou amino, ou R1 et R2 forment ensemble un radical alkylénedioxy faible ou benzo éventuellement substitué, et R3 représente (i) -(CH2)nNR10, R11, dans lequel n vaut 2 ou 3, et R10 et R11 représentent chacun un alkyle faible ou R10 et R11 forment ensemble, avec l'atome d'azote, un système de noyaux saturé azacyclique ou azabicyclique ; ou (ii) -(CH2)m-Q, dans lequel m vaut 0 ou 1 et Q est le résidu d'un système de noyaux saturé azacyclique ou azabicyclique, système couplé via un atome de carbone de celui-ci, ou un sel pharmacologiquement acceptable de celui-ci, pour le traitement de l'incontinence urinaire ou le syndrome d'irritation intestinale. La présente invention concerne aussi des composés nouveaux inclus dans la Formule (IA), des compositions pharmaceutiques de ceux-ci et la préparation desdits composés. |
Author | BEIERLEIN, KATARINA RINGBERG, ERIK SJOEBERG, BIRGER HARALDSSON, MARTIN JOHANSSON, ROLF AAKERBLOM, EVA WEINZ, BIRGITTA |
Author_xml | – fullname: AAKERBLOM, EVA – fullname: RINGBERG, ERIK – fullname: HARALDSSON, MARTIN – fullname: SJOEBERG, BIRGER – fullname: WEINZ, BIRGITTA – fullname: BEIERLEIN, KATARINA – fullname: JOHANSSON, ROLF |
BookMark | eNqNyk0KwjAQQOEsdOHfHeYAFRQVdTmOIw2mTZikaFalSFxJW6j3RwQP4OrBx5uqUdu1aaIiSjQUyVg0VywZCOVk79FoAvaBxWcQctYClecMXI5SIHEVNKEBsoWzXgdtSw9YnsEJOxT8wlyNn81rSItfZwouHChfpr6r09A3j9Smd32zx8Nqu1vvcb35Y_kAN_Ezcw |
ContentType | Patent |
DBID | EVB |
DatabaseName | esp@cenet |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Sciences |
DocumentTitleAlternate | ESTERS D'ARYLCYCLOALCANE CARBOXYLIQUES, LEUR EMPLOI, LEUR PREPARATION ET LEURS COMPOSITIONS PHARMACEUTIQUES |
Edition | 6 |
ExternalDocumentID | WO9804517A1 |
GroupedDBID | EVB |
ID | FETCH-epo_espacenet_WO9804517A13 |
IEDL.DBID | EVB |
IngestDate | Fri Jul 19 14:01:20 EDT 2024 |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English French |
LinkModel | DirectLink |
MergedId | FETCHMERGED-epo_espacenet_WO9804517A13 |
Notes | Application Number: WO1997SE01310 |
OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19980205&DB=EPODOC&CC=WO&NR=9804517A1 |
ParticipantIDs | epo_espacenet_WO9804517A1 |
PublicationCentury | 1900 |
PublicationDate | 19980205 |
PublicationDateYYYYMMDD | 1998-02-05 |
PublicationDate_xml | – month: 02 year: 1998 text: 19980205 day: 05 |
PublicationDecade | 1990 |
PublicationYear | 1998 |
RelatedCompanies | BEIERLEIN, KATARINA RINGBERG, ERIK SJOEBERG, BIRGER HARALDSSON, MARTIN JOHANSSON, ROLF AAKERBLOM, EVA WEINZ, BIRGITTA PHARMACIA & UPJOHN AB |
RelatedCompanies_xml | – name: RINGBERG, ERIK – name: WEINZ, BIRGITTA – name: HARALDSSON, MARTIN – name: PHARMACIA & UPJOHN AB – name: SJOEBERG, BIRGER – name: BEIERLEIN, KATARINA – name: AAKERBLOM, EVA – name: JOHANSSON, ROLF |
Score | 2.4842489 |
Snippet | The invention relates to the use of compounds of general Formula (IA) wherein: A is an optionally substituted cycloalkane ring having 3 to 6 carbon atoms and... |
SourceID | epo |
SourceType | Open Access Repository |
SubjectTerms | ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
Title | ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION |
URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=19980205&DB=EPODOC&locale=&CC=WO&NR=9804517A1 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NT4MwFG-WadSbTo3zKz0YTiNuDBgciOlKF6Z8BZiO0wJdTXZhi8P47_tgH3rRW9MmL-1LX99H-_sVoYdebvYFuBoZ3IEiq2omZMM0hKxoArazzvM5r-qQnq87E_V5qk0baLHDwtQ8oV81OSJYFAd7L-vzevVTxLLrt5Xrx3wBXcunUWLZ0nwHF4PoR5PsocXCwA6oRCnkbZIfWTCiar0BgUTpoIqiK5p99jqsQCmr3x5ldIoOQxBWlGeoIYoWOqa7j9da6Mjb3ndDc2t663OUkih1aUrdgLgvxGeYkmgYTFN3TDGLISiNOzhx2DjCk5h1cOiQyCOUTZKK8ADTwAuDeFxjhjHxbQyaD8mmQHWB8Igl1JFhjrO9PmZvwX41_UvULJaFuELYMLnIFD0zeYUf5YOs985zrd_NNF0Yhpq3UftPMdf_jN2gkw0OT5G72i1qlh-f4g4ccZnf1yr8Bqojhj0 |
link.rule.ids | 230,309,786,891,25594,76904 |
linkProvider | European Patent Office |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NT8IwFG8IGvGmqBE_ezA7sQhjG9uBmNKVbLKvbEPZiWyjJFwGkRn_fd_Gh1701rTJS_vS1_fR_n5F6Kmb6j0OrkYEdyCJspxwUdM1LkoKh-2sZuk8K-uQjquaE_l1qkxraLnHwlQ8oV8VOSJYVAb2XlTn9fqniGVUbys3z-kSulYvo2hgCPM9XAyiH0UwhgPme4ZHBUohbxPcYAAjstLtE0iUjvqQEZY0--xtWIJS1r89yugMHfsgLC_OUY3nTdSg-4_XmujE2d13Q3NnepsLFJMgtmlMbY_YY-IyTEkw9KaxbVHMQghKwzaOTGYFeBKyNvZNEjiEsklUEh5g6jm-F1oVZhgT18CgeZ9sC1SXCI9YRE0R5jg76GP27h1W07tC9XyV82uENT3jiaQmelbiR7N-0l1kqdLrJIrKNU1OW6j1p5ibf8YeUcOMHHtmW-74Fp1uMXmS2FHuUL34-OT34JSL9KFS5zcWwoko |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=ARYLCYCLOALKANE+CARBOXYLIC+ESTERS%2C+THEIR+USE%2C+PHARMACEUTICAL+COMPOSITIONS+AND+PREPARATION&rft.inventor=AAKERBLOM%2C+EVA&rft.inventor=RINGBERG%2C+ERIK&rft.inventor=HARALDSSON%2C+MARTIN&rft.inventor=SJOEBERG%2C+BIRGER&rft.inventor=WEINZ%2C+BIRGITTA&rft.inventor=BEIERLEIN%2C+KATARINA&rft.inventor=JOHANSSON%2C+ROLF&rft.date=1998-02-05&rft.externalDBID=A1&rft.externalDocID=WO9804517A1 |